Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

Funder: Canadian Institutes of Health Research

Funding period
CAD 115 K
USD 88 K
Funding amount
Abstract
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of drugs used to treat type 2 diabetes. These drugs have been shown to decrease the risk of fatal and non-fatal cardiovascular outcomes (such as heart attacks, strokes and death) in patients with type 2 diabetes in clinical trials. Despite their remarkable benefits, there have been concerns that these drugs might increase the risk of important adverse events including bladder cancer. To date, however, no studies have been conducted in the real-world setting to assess this possible association. To address this concern, we will conduct a large, international, multi-centre population-based cohort study using five administrative, primary care, and insurance databases from Canada, the United Kingdom, and the United States. At each site, we will compare new users of SGLT-2 inhibitors with new users of glucagon-like peptide-1 receptor agonists, a class of drugs used at a similar stage of diabetes severity. The results from each site will then be pooled together for an overall estimate of the effect of SGLT-2 inhibitors on bladder cancer. As patients with type 2 diabetes are already at an increased risk of bladder cancer, this large international study will provide concerned stakeholders with much needed information on the safety profile of these drugs in a timely and cost-effective fashion.
Similar projects All >
Sorted by: Start Date
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Chimeric RNAs and their implication in lymphatic metastasis of bladder cancer

National Cancer Institute to HUI LI

USD 205,913
2020 - 2025

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • RCDC

    Diabetes

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases

  • HRCS HC

    Metabolic and Endocrine

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science